Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IMUX 
Immunic Inc (IMUX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: IMUX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.47
1 Year Target Price $7.47
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.15% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 84.05M USD | Price to earnings Ratio - | 1Y Target Price 7.47 |
Price to earnings Ratio - | 1Y Target Price 7.47 | ||
Volume (30-day avg) 7 | Beta 1.44 | 52 Weeks Range 0.56 - 2.11 | Updated Date 09/12/2025 |
52 Weeks Range 0.56 - 2.11 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -88.95% | Return on Equity (TTM) -208.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 31692314 | Price to Sales(TTM) - |
Enterprise Value 31692314 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.21 | Shares Outstanding 98650600 | Shares Floating 65250460 |
Shares Outstanding 98650600 | Shares Floating 65250460 | ||
Percent Insiders 1.31 | Percent Institutions 53.6 |
Upturn AI SWOT
Immunic Inc
Company Overview
History and Background
Immunic Inc. is a biopharmaceutical company focused on developing orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Founded in 2016, it has advanced several clinical programs targeting diseases like relapsing-remitting multiple sclerosis (RRMS), psoriasis, and inflammatory bowel disease (IBD).
Core Business Areas
- Immunology: Development of selective oral immunomodulators for autoimmune and inflammatory diseases.
Leadership and Structure
Dr. Andreas Muehler is the CEO. The company operates with a functional organizational structure, comprising research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Vidofludimus calcium (IMU-838): An oral DHODH inhibitor being developed for RRMS, psoriasis, and IBD. It is currently in Phase 3 clinical trials for RRMS (CALLIPER trial). Competitors include Novartis (Gilenya), Biogen (Tecfidera), and Sanofi (Aubagio).
- IMU-935: An oral inverse agonist of RORyt being developed for psoriasis and potentially other autoimmune diseases. Currently in Phase 1 clinical trials. Competitors are primarily topical treatments or other systemic therapies like biologics from companies like Amgen and Eli Lilly.
Market Dynamics
Industry Overview
The autoimmune disease market is a large and growing market, driven by increasing prevalence of these diseases and the development of new therapies. Competition is intense, with many established pharmaceutical companies and smaller biotech companies vying for market share.
Positioning
Immunic focuses on developing oral therapies, which offer convenience and potentially better patient compliance compared to injectable biologics. Its competitive advantage lies in its selective DHODH and RORyt inhibitors and targeting specific pathways in the immune system.
Total Addressable Market (TAM)
The global autoimmune disease market is estimated at hundreds of billions of dollars. Immunic is targeting specific segments within this market, such as RRMS, psoriasis and IBD. Success in the clinical trials would allow Immunic to take a reasonable market share.
Upturn SWOT Analysis
Strengths
- Oral therapies offer convenience and potential for improved patient compliance.
- Targeted approach with selective DHODH and RORyt inhibitors.
- Strong intellectual property portfolio.
- Experienced management team.
Weaknesses
- Clinical trial risks and potential for failure.
- Dependence on successful development and commercialization of lead candidates.
- Limited financial resources compared to larger pharmaceutical companies.
- Currently No Revenue
Opportunities
- Positive clinical trial results could lead to rapid market adoption.
- Partnerships with larger pharmaceutical companies for development and commercialization.
- Expansion into new indications with existing or new drug candidates.
- FDA Fast Track designation
Threats
- Competition from established therapies and new entrants in the market.
- Regulatory hurdles and potential delays in approval.
- Patent challenges and loss of exclusivity.
- Unfavorable pricing and reimbursement policies.
Competitors and Market Share
Key Competitors
- NVS
- BIIB
- SNY
- LLY
Competitive Landscape
Immunic faces intense competition from established pharmaceutical companies with approved therapies. Its competitive advantage lies in its oral therapies.
Growth Trajectory and Initiatives
Historical Growth: Growth has been characterized by advancing clinical programs and securing funding.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely based on the perceived likelihood of success.
Recent Initiatives: Advancing Phase 3 trial for IMU-838 in RRMS and progressing Phase 1 trial for IMU-935.
Summary
Immunic Inc. is a clinical-stage biopharmaceutical company with potential in the autoimmune disease market, focusing on oral therapies. Their key success hinges on the positive results of the phase 3 trial. Immunic needs to successfully navigate regulatory hurdles and secure funding to advance its programs. The company's lack of revenue makes it dependent on successful clinical trial results and finding buyers to advance its programs. Given this, it faces risks of not finding the necessary financial support.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Immunic Inc. Investor Relations
- Company Filings (SEC)
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immunic Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2014-04-17 | CEO & Director Dr. Daniel Vitt Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 90 | Website https://imux.com |
Full time employees 90 | Website https://imux.com | ||
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.